

**PB 75 of 2024**

National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 25 June 2024

Nikolai Tsyganov

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 July 2024 2

National Health (Minimum Stockholding) Determination 2023 2

Schedule 2—Amendments commencing 1 October 2024 15

National Health (Minimum Stockholding) Determination 2023 15

Schedule 3—Amendments commencing 1 December 2024 17

National Health (Minimum Stockholding) Determination 2023 17

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024*.

 (2) This instrument may also be cited as PB 75 of 2024.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 July 2024. | 1 July 2024 |
| 2. Schedule 1 | 1 July 2024. | 1 July 2024 |
| 3. Schedule 2 | 1 October 2024. | 1 October 2024 |
| 4. Schedule 3 | 1 December 2024. | 1 December 2024 |

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 July 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Aripiprazole | Tablet 10 mg | Oral | Aripic Aripiprazole | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |

2 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atorvastatin | Tablet 10 mg (as calcium) | Oral | Atorvastatin GH | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Atorvastatin | Tablet 40 mg (as calcium) | Oral | Atorvastatin GH | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |

3 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atomoxetine | Capsule 80 mg (as hydrochloride) | Oral | APO‑Atomoxetine | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atorvastatin | Tablet 10 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Atorvastatin | Tablet 20 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Atorvastatin | Tablet 40 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | between 1 July 2024 and 31 August 2024—0months stock by reference to usual demand |
| Atorvastatin | Tablet 80 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Candesartan | Tablet containing candesartan cilexetil 16 mg | Oral | NOUMED CANDESARTAN | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 32 mg | Oral | NOUMED CANDESARTAN | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | NOUMED CANDESARTAN | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | NOUMED CANDESARTAN | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Capecitabine | Tablet 150 mg | Oral | Capecitabine-DRLA | between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand |

5 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Calcium | Tablet, chewable, 500 mg (as carbonate) | Oral | Cal‑500 | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Candesartan | Tablet containing candesartan cilexetil 16 mg | Oral | Blooms the Chemist Candesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 32 mg | Oral | Blooms the Chemist Candesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | Blooms the Chemist Candesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | Blooms the Chemist Candesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | Oral | Blooms the Chemist Candesartan HCTZ 32/12.5 | between 1 July 2024 and 31 August 2024— 0 months stock by reference to usual demand |
| Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | Oral | Blooms the Chemist Candesartan HCTZ 32/25 | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Capecitabine | Tablet 500 mg | Oral | Capecitabine-DRLA | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

6 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefepime | Powder for injection 1 g (as hydrochloride) | Injection | Omegapharm Pty Ltd | between 1 May 2024 and 31 May 2024—0 months stock by reference to usual demand |
| Cefepime | Powder for injection 2 g (as hydrochloride) | Injection | Omegapharm Pty Ltd | between 1 May 2024 and 31 May 2024—0 months stock by reference to usual demand |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clindamycin | Capsule 150 mg (as hydrochloride) | Oral | Clindamycin BNM | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |

8 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | Oral | Rivotril | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clopidogrel | Tablet 75 mg (as besilate) | Oral | BTC Clopidogrel | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

9 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Malean | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | Entecavir Mylan | after 30 September 2024— 4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together |

10 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Escitalopram | Tablet 10 mg (as oxalate) | Oral | APX‑Escitalopram | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Escitalopram | Tablet 10 mg (as oxalate) | Oral | Blooms the Chemist Escitalopram | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

11 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Escitalopram | Tablet 20 mg (as oxalate) | Oral | APX‑Escitalopram | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Escitalopram | Tablet 20 mg (as oxalate) | Oral | Blooms the Chemist Escitalopram | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Ezetimibe | Tablet 10 mg | Oral | Blooms The Chemist Ezetimibe | between 1 July 2024 and 31 July 2024—0 months stock by reference to usual demand |

12 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Plendil ER | 2.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fenofibrate | Tablet 145 mg | Oral | Blooms the Chemist Fenofibrate | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

13 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluorometholone | Eye drops 1 mg per mL, 5 mL | Application to the Eye | FML Liquifilm | 2 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluorometholone | Eye drops 1 mg per mL, 5 mL | Application to the Eye | FML Liquifilm | between 1 July 2024 and 31 January 2025—0 months stock by reference to usual demand |

14 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluorometholone | Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL | Application to the Eye | Flarex | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | BTC Fluoxetine | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

15 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Gamine XR | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glimepiride | Tablet 1 mg | Oral | Amaryl | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

16 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glucose and ketone indicator‑urine | Test strips, 50 (Keto‑Diastix) | For External Use | Keto‑Diastix | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Granisetron | Concentrated injection 3 mg (as hydrochloride) in 3 mL | Injection | Granisetron Kabi | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

17 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Insect allergen extract‑yellow jacket venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Yellow Jacket Venom | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Irbesartan | Tablet 150 mg | Oral | Blooms the Chemist Irbesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Irbesartan | Tablet 75 mg | Oral | Avapro | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Irbesartan | Tablet 75 mg | Oral | Blooms the Chemist Irbesartan | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Irbesartan with hydrochlorothiazide | Tablet 150 mg-12.5 mg | Oral | AVSARTAN HCT 150/12.5 | 4 months stock by reference to usual demand |

18 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the Eye | APO‑Latanoprost/Timolol 0.05/5 | 2.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Leflunomide | Tablet 10 mg | Oral | Arabloc | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | BTC Lercanidipine | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | BTC Lercanidipine | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

19 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Meloxicam | Tablet 7.5 mg | Oral | MELOBIC | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Blooms the Chemist Metformin XR 1000 | between 1 July 2024 and 31 July 2024—0 months stock by reference to usual demand |
| Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Blooms the Chemist Metformin XR 500 | between 1 July 2024 and 31 July 2024—0 months stock by reference to usual demand |

20 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Morphine | Tablet containing morphine sulfate pentahydrate 30 mg | Oral | Anamorph | 3 months stock by reference to usual demand |

21 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Norfloxacin | Tablet 400 mg | Oral | APO‑Norfloxacin | 2.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 10 mg | Oral | NOUMED OLANZAPINE | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

22 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together. |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 2.5 mg | Oral | NOUMED OLANZAPINE | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

23 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 20 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 5 mg | Oral | NOUMED OLANZAPINE | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

24 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral;(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 7.5 mg | Oral | NOUMED OLANZAPINE | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

25 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Periciazine | Tablet 2.5 mg | Oral | Neulactil | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | BTC Perindopril | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

26 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | Indosyl Mono 2 | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand(b) after 31 December 2023—5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | BTC Perindopril | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

27 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Indosyl Mono 4 | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand(b) after 31 December 2023—5.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | BTC Perindopril | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

28 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 300 mg | Oral | Cipla Pregabalin | between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 75 mg | Oral | Blooms the Chemist Pregabalin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

29 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Risperidone | Tablet 3 mg | Oral | Rispa | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Rosuvastatin | Tablet 10 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 20 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 40 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

30 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Roxithromycin | Tablet 150 mg | Oral | Roximycin | between 1 May 2024 and 30 June 2024—0 months stock by reference to usual demand |

31 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Roxithromycin | Tablet 300 mg | Oral | Roximycin | between 1 May 2024 and 30 June 2024—0 months stock by reference to usual demand |

32 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Asmol CFC-Free with dose counter | between 1 January 2024 and 30 June 2024—0 months stock by reference to usual demand |
| Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Zempreon CFC-Free with dose counter | between 1 January 2024 and 30 June 2024—0 months stock by reference to usual demand |

33 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 100 mg | Oral | NOUMED TOPIRAMATE | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |

34 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 200 mg | Oral | NOUMED TOPIRAMATE | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |

35 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 25 mg | Oral | NOUMED TOPIRAMATE | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |

36 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Topiramate | Tablet 50 mg | Oral | NOUMED TOPIRAMATE | between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand |

37 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Triglycerides, medium chain | Oral liquid 225 mL, 15 (K.Quik) | Oral | K.Quik | 0 months stock by reference to usual PBS demand |

38 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valproic acid | Tablet, crushable, containing sodium valproate 100 mg | Oral | Epilim | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Blooms the Chemist Venlafaxine XR | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |
| Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Blooms the Chemist Venlafaxine XR | between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand |

Schedule 2—Amendments commencing 1 October 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Acarbose | Tablet 100 mg | Oral | Acarbose Viatris | 4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together |

2 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Dosulepin | Tablet containing dosulepin hydrochloride 75 mg | Oral | Dosulepin Viatris 75 | 6 months stock by reference to usual demand of both Dosulepin Viatris 75 and Dosulepin Mylan added together |

3 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lamivudine with zidovudine | Tablet 150 mg-300 mg | Oral | Lamivudine/Zidovudine Viatris 150/300 | after 31 May 2024—4 months stock by reference to usual demand of both Lamivudine/Zidovudine Viatris 150/300 and Lamivudine 150 mg + Zidovudine 300 mg Alphapharm added together |

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Moxonidine | Tablet 200 micrograms | Oral | Moxonidine Viatris | 4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together |
| Moxonidine | Tablet 400 micrograms | Oral | Moxonidine Viatris | 4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together |

5 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Paraffin with retinol palmitate | Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g | Application to the Eye | VitA-POS | between 1 April 2024 and 30 September 2024—0 months stock by reference to usual demand |

6 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valganciclovir | Tablet 450 mg (as hydrochloride) | Oral | Valganciclovir Viatris | 4 months stock by reference to usual demand of both Valganciclovir Viatris and Valganciclovir Mylan added together |

Schedule 3—Amendments commencing 1 December 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Metronidazole | Suppositories 500 mg, 10 | Rectal | Flagyl | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Mifepristone and misoprostol | Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms | Oral | MS-2 Step | 6 months stock by reference to usual PBS demand |

2 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valganciclovir | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL | Oral | Valcyte | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000) | Oral | Valine 1000 | 6 months stock by reference to usual PBS demand |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50) | Oral | Valine 50 | 6 months stock by reference to usual PBS demand |